[Webinar] Monitoring Cancer Treatments with Immuno-PET

Webinar Overview The clinical use of full-length mAbs as imaging agents can be challenging, due to their long biological half-life and relatively slow tumor penetration, which may affect tumor-to-background contrast at early time points. To circumvent these issues, Dr Gabriela Kramer-Marek’s team has developed radiolabeled affibody-based PET tracers that still have high specificity and affinity of the potential therapeutic mAb, but their molecular weight below 60 kDa allows for rapid renal clearance and elimination.   Session 1 March 14th, 2019 10.00 am CET Register Now Session 2 March 14th, 2019 11.00 am EDT Register Now

Speakers

Dr Gabriela Kramer-Marek Team Leader Dr Gabriela Kramer-Marek received her Ph.D. degree in Medical Physics in 2005 from Silesian University, Poland, and the following year joined the Radiation Oncology Branch, NCI/NIH, Bethesda, USA, to work as a postdoctoral research fellow on the development and characterisation of molecular probes for in vivo detection and quantification of tumour-specific markers.       Dr Ali Asgar Attarwala Bruker BioSpin Joined Bruker BioSpin in 2018 as Application Scientist in the field of PreClinical Imaging (PCI) supporting PET/SPECT/CT and MR imaging. Previously, he studied Medical Physics at the University of Heidelberg where he graduated in 2017. During his time in Heidelberg he mainly focussed on optimization of quantitative imaging techniques and therapy planning in radiation oncology.